{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-227202","form_type":"8-K","ticker":null,"cik":"0001142596","company_name":"NUVASIVE INC","filed_at":"2023-09-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.238852+00:00","generated_at":"2026-06-11T00:22:03.005130+00:00","sec_items":["1.01","1.02","2.01","3.01","3.03","5.01","5.02","5.03","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"NuVasive completes merger with Globus Medical, shareholders get 0.75 GMED shares","bullets":["Merger closed Sep 1, 2023; NuVasive shareholders received 0.75 Globus Medical Class A shares per NUVA share.","NuVasive common stock to be delisted from Nasdaq after Form 25 filed; reporting obligations to be suspended.","CEO J. Christopher Barry and CFO Matthew Harbaugh depart; Daniel Scavilla named CEO, Keith Pfeil CFO of NuVasive.","All prior directors cease; Scavilla and Pfeil become directors; charter and bylaws amended.","Convertible notes and bond hedges amended; conversion rights now based on Globus Medical common stock."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-227202","json":"https://secwatch.observer/filing/0001193125-23-227202.json","markdown":"https://secwatch.observer/filing/0001193125-23-227202.md","text":"https://secwatch.observer/filing/0001193125-23-227202.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1142596/000119312523227202/0001193125-23-227202-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1142596/000119312523227202/d469541d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T00:22:03.005130+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"42ff49fc20","claim":"Michael Farrington departed as senior vice president at NUVASIVE INC.","evidence_excerpt":"each of Michael Farrington, Nathaniel B. Sisitsky and Dale Wolf ceased to be senior vice presidents of NuVasive","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1142596/000119312523227202/0001193125-23-227202-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased"},{"label":"Role","value":"senior vice president"}],"fact_type":"executive_change"},{"claim_id":"4441ee4728","claim":"Daniel Scavilla was appointed as director at NUVASIVE INC.","evidence_excerpt":"Daniel Scavilla and Keith Pfeil, each a director of Merger Sub immediately prior to the Effective Time, became a director of NuVasive","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1142596/000119312523227202/0001193125-23-227202-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"53b7be4caa","claim":"Nathaniel B. Sisitsky departed as senior vice president at NUVASIVE INC.","evidence_excerpt":"each of Michael Farrington, Nathaniel B. Sisitsky and Dale Wolf ceased to be senior vice presidents of NuVasive","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1142596/000119312523227202/0001193125-23-227202-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased"},{"label":"Role","value":"senior vice president"}],"fact_type":"executive_change"},{"claim_id":"7177c45e9f","claim":"Dale Wolf departed as senior vice president at NUVASIVE INC.","evidence_excerpt":"each of Michael Farrington, Nathaniel B. Sisitsky and Dale Wolf ceased to be senior vice presidents of NuVasive","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1142596/000119312523227202/0001193125-23-227202-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased"},{"label":"Role","value":"senior vice president"}],"fact_type":"executive_change"},{"claim_id":"e6996ccb4b","claim":"Keith Pfeil was appointed as director at NUVASIVE INC.","evidence_excerpt":"Daniel Scavilla and Keith Pfeil, each a director of Merger Sub immediately prior to the Effective Time, became a director of NuVasive","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1142596/000119312523227202/0001193125-23-227202-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"1a216a8127527fd773e175649f51ffed71b6c89c","claim":"NUVASIVE INC underwent a change of control involving Globus Medical, Inc. for 0.75 fully paid and non-assessable shares of Globus Medical Class A Common Stock per share of NuVasive Common Stock (closed 2023-09-01).","evidence_excerpt":"immediately prior to the Effective Time (other than certain excluded shares as described in the Merger Agreement) was cancelled and converted into the right to receive 0.75 fully paid and non-assessable shares (the “Exchange Ratio” and such shares, the “Merger Consideration”) of Globus Medical Class A Common Stock, with cash in lieu of fractional","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1142596/000119312523227202/0001193125-23-227202-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"Globus Medical, Inc."},{"label":"Consideration","value":"0.75 fully paid and non-assessable shares of Globus Medical Class A Common Stock per share of NuVasive Common Stock"},{"label":"Closing","value":"2023-09-01"}],"fact_type":"ma_transaction"},{"claim_id":"142843d03edde21323f5d32e195e72cdcee7ea32","claim":"NUVASIVE INC terminated Second Amended and Restated Credit Agreement with Bank of America, N.A. (effective 2023-09-01).","evidence_excerpt":"the Company terminated all commitments and repaid in full all obligations due under the Second Amended and Restated Credit Agreement, dated as of February 24, 2020","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1142596/000119312523227202/0001193125-23-227202-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Bank of America, N.A."},{"label":"Effective","value":"2023-09-01"}],"fact_type":"material_agreement"},{"claim_id":"40a931e143188412d2df74e54a974d3a5f5929ae","claim":"NUVASIVE INC entered into First Supplemental Indenture with Wilmington Trust, National Association (effective 2023-09-01).","evidence_excerpt":"on the Closing Date, the Company, Globus Medical and Wilmington Trust, National Association (the “Trustee”) entered into that certain First Supplemental Indenture (the “Supplemental Indenture”) to the indenture dated as of March 2, 2020","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1142596/000119312523227202/0001193125-23-227202-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"Wilmington Trust, National Association"},{"label":"Effective","value":"2023-09-01"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}